Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 4/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.45 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.45 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.45 |
| ▸ | PLCG1 | P19174 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | MELK | Q14680 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4781461 | 0.92 | HPGDS (0.48) | HPGDSPIP4K2APIP4K2BPIP4K2CPLCG1 | |
| SCHEMBL4794193 | 0.90 | HPGDS (0.52) | HPGDSPIP4K2APIP4K2BPIP4K2CPIK3C3 | |
| SCHEMBL4794538 | 0.86 | HPGDS (0.50) | HPGDSPIP4K2APIP4K2BPIP4K2CPIK3C3 | |
| SCHEMBL4796970 | 0.85 | PIP4K2A (0.63) | HPGDSPIP4K2APIP4K2BPIP4K2CPLCG1 | |
| SCHEMBL3928845 | 0.82 | HPGDS (0.57) | HPGDSPIP4K2APIP4K2BPIP4K2CPIK3C3 | |
| SCHEMBL3929850 | 0.81 | HPGDS (0.45) | HPGDSPIK3C3ABL1PIK3CGJAK3 | |
| SCHEMBL3929164 | 0.80 | PIK3CD (0.58) | HPGDSPIP4K2APIP4K2BPIP4K2CPIK3C3 | |
| SCHEMBL4793977 | 0.79 | HPGDS (0.47) | HPGDSPIP4K2APIP4K2BPIP4K2CPIK3C3 | |
| SCHEMBL4793555 | 0.78 | HPGDS (0.49) | HPGDSPIP4K2APIP4K2BPIP4K2CPIK3C3 | |
| SCHEMBL4794592 | 0.78 | HPGDS (0.48) | HPGDSPIP4K2APIP4K2BPIP4K2CPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | claimed |
| US-7504401-B2 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | claimed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | claimed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | claimed |
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-7504401-B2 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | HPGDS 2149/4885FGFR1 1455/4885PIP4K2A 4139/4885 |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | HPGDS 2109/4885FGFR1 1475/4885PIP4K2A 4090/4885 |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | NR2E3, RB1, CBR3 | HPGDS 2387/4885FGFR1 1437/4885PIP4K2A 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.